Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History

Sermorelin peptide research occupies an unusual place in the peptide literature: this is one of the few research peptides that was once an FDA-approved prescription product. Sermorelin is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone — GHRH(1-29) — the shortest fragment of the natural 44-amino-acid hormone that retains full biological activity. In laboratory research it is used to probe how the pituitary gland synthesizes and releases growth hormone (GH), how GH pulsatility is regulated, and how the GH–IGF-1 axis responds when its normal feedback controls are left intact. This article reviews the mechanism, the human study record, the regulatory history, and the laboratory quality checks that matter — strictly in a research-use-only context. Research-grade material such as the Sermorelin research peptide supplied by Apex Bio Industries is not an approved drug and is sold solely for laboratory research.

What Sermorelin Is: The 1-29 Fragment of GHRH

Natural human GHRH is a 44-amino-acid peptide released by the arcuate nucleus of the hypothalamus. Structure–activity studies in the 1980s showed that the receptor-binding and activation domain sits entirely in the first 29 residues: remove the C-terminal 15 amino acids and the fragment still activates the GHRH receptor fully. That fragment, amidated at its C-terminus, is sermorelin (also written GRF 1-29 NH2).

Two structural details drive much of the sermorelin peptide research story. First, sermorelin contains only natural L-amino acids and no stabilizing modifications — it is an exact copy of the human GHRH(1-29) sequence. Second, that fidelity is also its weakness: the Ala2–Asp3 bond is rapidly cleaved by the enzyme dipeptidyl peptidase-IV (DPP-IV), and the methionine at position 27 is prone to oxidation. The result is a plasma half-life of roughly 10–20 minutes. Later GHRH analogues — Modified GRF (1-29), CJC-1295, and tesamorelin — were engineered specifically to work around those two liabilities, which is why sermorelin remains the reference compound against which the modified versions are compared.

Mechanism of Action: Asking the Pituitary, Not Replacing the Hormone

Sermorelin binds the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor activation stimulates adenylyl cyclase, raising intracellular cAMP and activating protein kinase A. That cascade does two things at once: it triggers exocytotic release of stored GH granules, and it promotes transcription of the GH gene itself — synthesis as well as secretion.

The defining feature for researchers is what sermorelin does not override. Because it works through the pituitary rather than supplying GH directly:

• Pulsatility is preserved. GH is released in discrete pulses resembling the natural secretory pattern, rather than as the flat, sustained elevation produced by exogenous GH.
• Feedback stays intact. Rising GH and IGF-1 still feed back through somatostatin and hypothalamic pathways, so the axis retains its own braking system. A pituitary that cannot respond will not respond — sermorelin cannot force GH out of an exhausted or damaged gland.
• Downstream signaling is physiological in shape. GH released in pulses stimulates hepatic and peripheral IGF-1 production with the timing the axis normally produces, which is exactly the variable many study designs want to isolate.

This is also what separates sermorelin mechanistically from the other major secretagogue family. Ghrelin-mimetic peptides such as ipamorelin act at a completely different receptor (GHS-R1a) and primarily discharge preformed GH. Sermorelin peptide research therefore tends to ask pituitary-capacity questions — can this gland still make and release GH, and how does the pulse pattern change with age or disease — rather than simple output questions.

What the Human Studies Found

Pediatric growth hormone deficiency

Sermorelin’s most complete human dataset is in children with idiopathic GH deficiency and growth failure — the population for which it was once approved. Published pediatric cohorts (including the long-term treatment studies summarized by Prakash and Goa in their review of the drug) reported growth velocity roughly doubling in the first treatment year — from around 4.5 cm/year before treatment to around 9 cm/year — with gains maintained in multi-year follow-up and no neutralizing-antibody problem emerging as a barrier. Those results are the reason a GHRH fragment, rather than only recombinant GH, was taken seriously as a therapeutic concept: in children whose pituitaries retained GH-making capacity, stimulating the gland worked.

Diagnostic use: testing GH reserve

Sermorelin was also marketed in a diagnostic formulation (Geref Diagnostic) to assess pituitary GH secretory capacity. The logic follows directly from the mechanism: give the GHRH signal, measure the GH response, and a flat response localizes the problem to the pituitary rather than the hypothalamus. That diagnostic framing is still how much of the research literature uses the compound — as a standardized probe of somatotroph reserve.

Adult and aging-axis studies

In adults, studies by Khorram and colleagues and by Vittone and colleagues measured GH and IGF-1 responses to sermorelin in older subjects, whose natural GH pulse amplitude declines with age. The consistent finding was an added, receptor-driven GH pulse — integrated GH output over the monitoring window roughly doubling in the first hours after administration in cell and human study reports — with spontaneous background pulsatility otherwise largely intact and no clear desensitization over repeated evaluation in those study periods. What the adult literature does not contain is large, long-duration, outcome-based trials: there are no Phase 3-style adult studies establishing effects on body composition endpoints, fracture, mortality, or other hard outcomes. Honest sermorelin peptide research summaries should say so plainly — the adult evidence is pharmacodynamic (it moves GH and IGF-1) rather than outcome-proven.

Sermorelin vs the Other GH-Axis Peptides

For a lab choosing between them, the practical question is which experimental variable matters: sermorelin offers the native sequence and the shortest, cleanest pulse; the modified analogues trade that fidelity for duration. Confusing the molecules on an order or a COA — a real risk, since several share the “GRF 1-29” nickname — invalidates a study design, which is why identity testing (below) is not a formality.

Regulatory Status: Approved Once, Discontinued, Not Currently an Approved Drug

Sermorelin acetate was developed by Serono Laboratories and approved by the US FDA in 1997 under the brand name Geref for children with GH deficiency or growth failure, alongside the Geref Diagnostic formulation for GH-reserve testing. In 2008 the manufacturer (by then EMD Serono) voluntarily discontinued the products. The discontinuation was for commercial and manufacturing reasons — it was not a safety withdrawal, and the FDA has issued no sermorelin safety communication since. No FDA-approved sermorelin product is currently marketed, and sermorelin is not centrally approved by the EMA as a medicine.

Three status points researchers should keep separate:

• Historical approval ≠ current approval. The Geref history means the molecule has a characterized human pharmacology record — it does not make any present-day research material an approved drug.
• Compounded versions are a separate category. Sermorelin obtained through compounding channels is not the discontinued FDA-approved product and is outside the scope of this article.
• Sport prohibition. GHRH and its analogues, including sermorelin, fall under the WADA Prohibited List’s S2 class (peptide hormones and releasing factors) and are prohibited at all times in sport.

Material sold as RUO — the way the peptide-research community shorthand “ruo” is meant, alongside slang like “peps” or “peppers” — is supplied strictly for laboratory research use only, regardless of the compound’s prescription history.

Laboratory Considerations: Identity, Purity, and Handling

Confirming you actually have sermorelin

Sermorelin’s expected monoisotopic-average molecular weight is 3357.93 Da, so a mass-spectrometry result on a certificate of analysis should center on that mass (commonly observed as multiply charged ESI species, e.g. [M+2H]2+ near m/z 1680). That single check separates sermorelin from Modified GRF (1-29) (~3368 Da) and from truncated or deletion sequences left over from synthesis. Purity is the complementary number: reversed-phase HPLC reports the percentage of total peak area in the main peak, as explained in our guide to peptide HPLC purity testing. Apex Bio’s approach to both checks is described on its COA & third-party testing page.

Stability watch-outs specific to this sequence

• Methionine oxidation. The Met27 residue can oxidize (+16 Da on mass spec), which reduces receptor activity — a degradation product worth looking for on the chromatogram, not just in the headline purity figure.
• Enzymatic fragility. The same DPP-IV sensitivity that shortens sermorelin’s half-life in plasma makes it a poor candidate for casual handling in non-sterile, enzyme-bearing solutions in vitro; study protocols account for this explicitly.
• Standard lyophilized handling. Store the lyophilized peptide desiccated and frozen for the long term, equilibrate the sealed vial to room temperature before opening to keep condensation out, and treat reconstituted solutions as short-lived refrigerated material. Our peptide research library collects the related storage and handling guides.

Frequently Asked Questions

Is sermorelin the same as CJC-1295?

No. Sermorelin is the unmodified human GHRH(1-29) sequence. “CJC-1295 No DAC” is Modified GRF (1-29) — the same backbone with four substitutions that resist enzymatic cleavage — and the DAC form adds an albumin-binding complex. They share a receptor, not an identity, and their masses differ on a COA.

Was sermorelin banned or withdrawn for safety?

No. The FDA-approved Geref products were voluntarily discontinued by the manufacturer in 2008 for commercial reasons. Discontinuation is not a safety finding — but it also means no approved sermorelin product is sold today.

Why is the half-life so short if it was a real drug?

Because it is an exact copy of a natural fragment, sermorelin is cleaved by DPP-IV within minutes (~10–20 minute half-life). The approved products were used in settings where a brief, controllable pulse was acceptable — including diagnostic testing, where a short action is actually desirable.

Does sermorelin suppress natural GH production?

The published mechanism argues the opposite shape of effect: sermorelin acts upstream at the pituitary and leaves somatostatin and IGF-1 feedback intact, so it does not bypass the axis the way exogenous GH does. That is a mechanistic statement from the literature, not a guarantee about any individual protocol — and it is one reason the compound remains a research tool for studying the intact axis.

How do I verify a sermorelin COA?

Check three things: the mass-spec identity matches 3357.93 Da, the HPLC purity figure is reported as main-peak area percentage with the chromatogram shown, and the batch number on the certificate matches the vial in hand. Our COA-reading and HPLC guides walk through each step.

Related in the Apex shop: Sermorelin research peptide — supplied strictly for laboratory research use.

Disclaimer: This article is for educational and laboratory research purposes only. Sermorelin supplied by Apex Bio Industries is sold strictly as a research-use-only (RUO) material. It is not intended for human or veterinary use, not for diagnostic or therapeutic use, and not a drug, food, or dietary supplement. No statement in this article is a claim of efficacy or safety for any use outside laboratory research. Researchers are responsible for complying with all applicable laws, institutional policies, and laboratory safety requirements.